Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Kaleido Biosciences, Inc.
WARNING LETTER
•Kaleido Biosciences, Inc.•March 3, 2021

Kaleido Biosciences, Inc. – FDA Warning Letter, Mar 3, 2021

Record Details

This FDA Warning Letter, dated September 7, 2021, addresses Kaleido Biosciences, Inc. (Kaleido) regarding objectionable conditions observed during an FDA inspection from February 24 to March 3, 2021. The inspection, part of FDA’s Bioresearch Monitoring Program, evaluated Kaleido’s role as sponsor for clinical investigations of investigational drug KB109.

The primary violation identified is Kaleido's failure to submit Investigational New Drug (IND) applications for clinical investigations of KB109, specifically Protocols K031-120 and K032-120, which involved 350 and 49 human subjects, respectively. FDA regulations (21 CFR 312.20(a), 312.20(b), and 312.40(a)) require an IND before initiating clinical investigations of a drug subject to 21 CFR 312.2(a), unless exempt.

Kaleido argued KB109 was a food, not a drug, and the studies evaluated its effect on the microbiome and safety/tolerability in COVID-19 patients, not as a treatment. They cited GRAS status and potential as a medical food. However, FDA concluded KB109 was intended as a drug based on study objectives and endpoints, which assessed efficacy in mitigating and treating COVID-19

Company
Kaleido Biosciences, Inc.
Inspection date
March 3, 2021
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • David C. Burrow (Director )
  • Miah Jung
View Company Profile

ID · 7233646a-f340-4855-bb1d-77249fb63b59

Violation Codes7
21 CFR 31221 CFR 312.20(a)21 CFR 312.20(b)21 CFR 312.40(a)FD&C Act 50521 U.S.C. 321(g)(1)21 CFR 312.2

Full citation text and observation details available on the Dashboard.

Other documents for Kaleido Biosciences, Inc.
  • 483 - 2021-03-03March 3, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Kaleido Biosciences, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.